BR100 Increased By (0.95%)
BR30 Increased By (1.07%)
KSE100 Increased By (0.98%)
KSE30 Increased By (1.05%)
AGHA 6.39 Increased By ▲ 0.01 (0.16%)
BECO 4.38 Increased By ▲ 0.03 (0.69%)
BML 62.97 Increased By ▲ 0.42 (0.67%)
BOP 31.44 Increased By ▲ 0.05 (0.16%)
CNERGY 11.77 Increased By ▲ 0.04 (0.34%)
CSIL 5.79 Decreased By ▼ -0.12 (-2.03%)
FCCL 61.82 Increased By ▲ 0.11 (0.18%)
FFL 14.85 Increased By ▲ 0.06 (0.41%)
FNEL 1.30 Increased By ▲ 0.06 (4.84%)
KEL 6.34 Increased By ▲ 0.02 (0.32%)
KOSM 5.82 Decreased By ▼ -0.08 (-1.36%)
LOTCHEM 24.80 Increased By ▲ 0.11 (0.45%)
MLCF 106.14 Increased By ▲ 2.21 (2.13%)
NBP 174.50 Increased By ▲ 1.18 (0.68%)
NCPL 52.50 Increased By ▲ 0.67 (1.29%)
NPL 54.80 Increased By ▲ 0.77 (1.43%)
OGDC 318.80 Increased By ▲ 2.93 (0.93%)
PACE 9.30 Increased By ▲ 0.04 (0.43%)
PAEL 35.85 Increased By ▲ 0.27 (0.76%)
PIBTL 14.21 Increased By ▲ 0.55 (4.03%)
PPL 229.99 Increased By ▲ 3.92 (1.73%)
PRL 81.50 Increased By ▲ 1.22 (1.52%)
PTC 46.84 Increased By ▲ 0.20 (0.43%)
SSGC 24.13 Increased By ▲ 0.31 (1.3%)
TBL 9.32 Increased By ▲ 0.08 (0.87%)
TELE 7.60 Increased By ▲ 0.05 (0.66%)
TPL 24.69 Increased By ▲ 0.15 (0.61%)
TPLP 12.91 Decreased By ▼ -0.08 (-0.62%)
TREET 26.51 Increased By ▲ 0.53 (2.04%)
TRG 53.74 Increased By ▲ 0.41 (0.77%)
World

Novavax Covid vaccine highly effective against severe Covid: company

  • The results announced Thursday were from final analyses, following interim results that were announced in late January.
Published Updated
By

WASHINGTON: US biotech firm Novavax's Covid-19 vaccine was shown to be 100 percent protective against severe cases of the disease, including hospitalization and death, the company said Thursday following trials.

But its efficacy against the South African variant fell markedly when including mild and moderate cases, results showed.

The results announced Thursday were from final analyses, following interim results that were announced in late January.

In a Phase 3 trial in Britain that included 15,000 participants aged 18-84, including 27 percent over the age of 65, efficacy against mild, moderate and severe Covid was 96.4 percent against the original strain.

This fell to 89.7 when including people infected with the B.1.1.7 variant, which has been shown to be more transmissible and cause more severe disease.

In South Africa, a smaller Phase 2b trial of some 2,600 people found it was 48.6 percent effective, though the figure rose to 55.4 percent among HIV-negative volunteers.

Across both trials, the vaccine known as NVX-CoV2373 demonstrated 100 percent protection against severe disease.

Unlike the Pfizer, Moderna and AstraZeneca vaccines, which deliver the genetic instructions that make human cells create a key protein of the virus, the Novavax shot injects synthetic versions of these proteins directly into the body to evoke an immune response.

The Maryland-based company has said it hopes to file for British approval of its Covid-19 vaccine at the start of the second quarter of 2021, and to do the same soon after in the United States.

Comments

Comments are closed for this article.